Establishing a world-class translational cancer center


Madrid – Spain has started an offensive to cut the time from bench to clinic. In mid-June, Science Minister Cristina Garmendia signed a contract with President of Madrid Esperanza Aguirre and Mariano Barba­cid, the director of Spain’s National Cancer Center (CNIO) to establish a new CNIO “Clinical Research Programme” at the Madrid-based hospital of Fuenlabrada. The programme, which will be led by Manuel Hidalgo from John Hopkins Hospital (Baltimore), a specialist in gastrointestinal cancer, will focus on translational cancer research – the transfer of experimental therapies from animal models to patients.
To accomplish this, three units – a clinical research unit in which new drugs can be tested on 1,500 patients per year, a diagnostic imaging unit and a cancer genomics unit – will work with researchers from the CNIO. One goal will be to identify and clinically validate biomarkers that indicate cancer disease progression. That could in turn offer novel cancer approaches to late-stage cancer patients, and optimise chemotherapy and targeted therapies to individuals. Another goal will be to identify relevant cancer genes by high-throughput sequencing of patient DNA in order to find novel pathways that could be targeted by small molecules or biologicals.
Barbacid said that the programme is “a pioneer in Spain” and that it would make Fuenlabrada one of the world’s top-10 centres for preclinical cancer research. In its five-year strategic plan, the CNIO has defined the goals of its new clinical units there for the design, implementation and analysis of Phase I and II clinical studies with novel anti-tumorigenic agents. The center wants to hire researchers with a focus on late preclinical drug development, pharmacokinetics, biomarker discovery and molecular imaging, and also join forces with external research groups. In a first sucess, German oncologist Christopher Heeschen from the University Munich has agreed to coordinate a group examining cancer stem cells in order to develop strategies to destroy them.
Initial funding will come from Spain’s Ministries of Science and Innovation, Health and Social Policy as well as Madrid’s health authorities. The Caja Madrid foundation will donate state-of-the-art equipment to the project.



Milan – Everyone agrees that Italy is not Greece, but it is common wisdom that the country could also be doing better. Considering the meagre growth of the Italian economy in the last decade however, data fom the 2011 survey of...



Milan – Italian drugmaker Newron Pharmaceuticals S.p.A. and Merck Serono have broadened the scope of their 5-year-old collaboration on CNS drugs. In addition to the Parkinson’s treatment safinamide, under the terms of a new...



Milan/Berlin – Swiss-Italian biotech Philogen SpA has revoked its plan to sell a 23% stake worth EUR65.3m and go public on the Milan stock exchange this Friday. The move came after German Bayer HealthCare unexpectedly terminated...



Rome – The EUR2.5m ERC Advanced Grants are the Grammies of European science – not in the same league as a Nobel Prize, but still a lucrative honor. In the fourth round since 2007, the European Research Council awarded some a590m...



Modena/London – Researchers from Germany, Italy and the UK have identified a molecule that is key to the onset of addiction and also involved into memory formation (EMBO Journal, doi:10.1038/emboj.2010.279). According to results...



Genoa/Philadelphia — The inexpensive anti-gout drug allopurinol can counteract colorectal adenoma progression, according to data presented yesterday at the 9th Annual AACR Frontiers in Cancer Prevention Research Conference...

Displaying results 11 to 20 out of 181

< Previous 11-20 Next >

© 2007-2016 BIOCOM


Current issue

All issues

Product of the week


Job Advert


As a company at the leading edge of genomics, the focus at Illumina is research and development. We take our employees seriously. From colleagues to career path to meeting professional goals, we help you find opportunities to grow your career. more...


All videos

Stock list

All quotes


  • PAION (D)1.77 EUR63.89%
  • 4SC (D)2.95 EUR11.32%
  • BIONOR PHARMA (N)0.86 NOK8.86%


  • STENTYS (F)2.83 EUR-26.30%
  • KARO BIO (S)24.60 SEK-16.04%


  • VERONA PHARMA (UK)3.40 GBP25.9%
  • IXICO (UK)35.75 GBP21.2%
  • SERODUS (N)2.71 NOK15.8%


  • BIONOR PHARMA (N)0.86 NOK-47.2%
  • STENTYS (F)2.83 EUR-44.3%
  • MOLMED (I)0.24 EUR-35.1%


  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)24.60 SEK3053.8%
  • 4SC (D)2.95 EUR243.0%


  • BIOTEST (D)13.79 EUR-85.3%
  • EVOCUTIS (UK)0.08 GBP-69.2%

No liability assumed, Date: 13.02.2016


All Events